SCHEMBL984847

SCHEMBL984847

CC(C)(C)OC(=O)Nc1ccc(C2(Cc3ccccc3)CC(=O)N(Cc3ccccc3)C2=O)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 2/20 0.42
NPY1R P25929 1/20 0.42
PTGDR2 Q9Y5Y4 2/20 0.41
DRD2 P14416 1/20 0.41
GLS O94925 1/20 0.40
ALDH1A1 P00352 1/20 0.40
KMT2A Q03164 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
NPFFR1 Q9GZQ6 1/20 0.38
NPFFR2 Q9Y5X5 1/20 0.38
P2RX7 Q99572 1/20 0.38
CYP17A1 P05093 1/20 0.38
SCD O00767 1/20 0.37
GRIN2B Q13224 1/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA7 P43166 1/20 0.37
CA14 Q9ULX7 1/20 0.37
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1990244 0.86 NPY1R (0.43) NAMPTNPY1RPTGDR2DRD2GLS
SCHEMBL12923043 0.79 ELANE (0.37) PTGDR2ALDH1A1
SCHEMBL984328 0.75 CYP19A1 (0.52) PTGDR2KMT2A
SCHEMBL29537418 0.73 NPY1R (0.49) NAMPTNPY1RPTGDR2DRD2ALDH1A1
SCHEMBL984665 0.73 NPY1R (0.49) NAMPTNPY1RPTGDR2DRD2ALDH1A1
SCHEMBL23769013 0.71 ALDH1A1 (0.51) NPY1RALDH1A1KMT2ALMNA
SCHEMBL30191291 0.71 ALDH1A1 (0.51) NPY1RALDH1A1KMT2ALMNA
SCHEMBL27376642 0.71 NPY1R (0.54) NPY1RDRD2
SCHEMBL981023 0.70 ATM (0.40) PTGDR2KMT2APDE4APDE4BPDE4C
SCHEMBL981672 0.70 ATM (0.40) PTGDR2KMT2APDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257545-B1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMANN LA ROCHE (CH) 2011-08-31 EP disclosed
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMAN-LA ROCHE, INC. (US) 2011-01-27 US disclosed
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMAN-LA ROCHE, INC. (US) 2011-01-27 US disclosed
EP-2257545-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF F. Hoffmann-La Roche AG (CH) 2010-12-08 EP disclosed
WO-2009115427-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2009-09-24 WO disclosed
WO-2009115427-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF SLC6A3, MAOB, TPH2 NAMPT 499/4885NPY1R 67/4885PTGDR2 373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.